Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8884585 | 0.88 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8884584 | 0.88 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31705067 | 0.87 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31210192 | 0.86 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12151850 | 0.85 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29998888 | 0.85 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16023839 | 0.85 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29323337 | 0.85 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1376688 | 0.85 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12150018 | 0.85 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011359-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2025-01-09 | — | — | US | disclosed |
| US-20240150391-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117357548-A | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4286519-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-111228288-B | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3137479-B1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11739114-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220306676-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11299511-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2022-04-12 | — | — | US | disclosed |
| CN-111228288-A | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-106459134-A | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20150337314-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-11-26 | — | — | US | disclosed |
| WO-2015168310-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2015-11-05 | — | — | WO | disclosed |
| EP-0882059-B1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5859233-A | PROTECTED 3'-AMINO GROUP-5'-PHOSPHORAMIDITE MONOMERS FOR USE IN SOLID PHASE SYNTHESIS, FORMING A STABLE, NUCLEASE RESISTANCE DNA | LYNX THERAPEUTICS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| US-5824793-A | ACTIVATING A 3'-DEPROTECTED AMINONUCLEOSIDE-5-PHOSPHORAMIDITE WITH TETRAZOLE AND REACTING WITH A 3'-PROTECTED AMINONUCLEOSIDE-5-PHOSPHORAMIDITE; OXIDATION OF THE PHOSPHORUS; | LYNX THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5684143-A | ACID STABILITY; DNA AND RNA DUPLEXES AND TRIPLEXES | LYNX THERAPEUTICS, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| WO-1997037691-A1 | TELOMERASE INHIBITORS | LYNX THERAPEUTICS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337314-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | SLC28A1 322/4885SLC28A2 273/4885SLC29A1 367/4885 |
| US-11739114-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | SLC28A1 322/4885SLC28A2 273/4885SLC29A1 367/4885 |
| US-20220306676-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | RNGTT, NSUN2, POLN | SLC28A1 322/4885SLC28A2 273/4885SLC29A1 367/4885 |
| US-11299511-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | SLC28A1 322/4885SLC28A2 273/4885SLC29A1 367/4885 |
| US-20240150391-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | RNGTT, NSUN2, POLN | SLC28A1 303/4885SLC28A2 278/4885SLC29A1 361/4885 |
| US-20250011359-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | RNGTT, NSUN2, POLN | SLC28A1 303/4885SLC28A2 278/4885SLC29A1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.